Abstract:
This invention relates a process for preparing octreotide and derivatives thereof. The starting material, Thr(ol)(tBu)-2-chlorotrityl resin is coupled with the various amino acids. The straight peptide-resin of D-Phe-Cys(Trt)-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(ol)(tBu)-2-chlorotrityl resin or D-Phe-Cys(Trt)-Tyr(tBu)-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(ol)(tBu)-2-chlorotrityl resin was obtained. Cleavage of the peptide from the resin was achieved by strong acid solution. The cleaved peptide reacted with charcoal to give disulfide-containing peptide of

Description:
FIELD OF THE INVENTION 
     The present invention relates to a novel synthesis of octreotide and derivatives thereof by solid phase peptide synthesis. In particular, the present invention relates to synthesize linear peptides, cleave from resin and the cyclization process for their preparation. 
     BACKGROUND OF THE INVENTION 
     Octreotide is a somatostatin analog which is inhibited the growth of tumor cell by binding the analog to the somatostatin receptor that located on the surface of tumor cell. The high binding affinity of the octreotide with the somatostatin receptor has been utilized as a tumor-visualization agent by labeled the octreotide with radioisotope. In-DTPA-octreotide (Octreo-Scan III) have been successfully used to visualized somatostatin receptor-positive tumors by gamma camera scintigraphy. 
     Octreotide comprises 8 amino acids which has the following structural formula:                           
     wherein sulfur atoms of the Cys at the position 2 and of the Cys at the position 7 are mono-cyclic to form an -S-S-bridge. Tyr-3-octreotide is a octreotide derivative thereof which Phe at the position 3 is replaced by Tyr. 
     Synthesis of octreotide and derivative thereof can be carried out by two methods. The first method is synthesized initially by fragment condensation solution phase procedures. The synthetic process of octreotide has been described by Bauer et al (Eur. Pat. Appl. 29,579,1981 and U.S. Pat. No. 4,395,403, 1983). 
     The process comprises: &lt;i&gt; removing protected group from peptide; &lt;ii&gt; linking together by an amide bond two peptide unit; &lt;iii&gt; converting a function group at the N- or C-terminal; &lt;iv&gt; oxidizing a straight chain polypeptide by boron tristrifluoroacetate. This process involves a time-consuming, multi-step synthesis, and it is difficult to separate octreotide from the reaction mixtures since all the synthesis steps are carried out in liquid phase. 
     The second method is synthesized by solid-phase procedures. Edward et al isolated side chain protected [D-Trp(Boc) 4 , Lys(Boc) 5 , Thr(Bu t ) 6 ]-octreotide with a total yield of 14% by cleaving the protected peptide from the resin with threoninol (J. Med. Chem. 1994,37,3749-3757). Arano et al carried out another solid phase method for DTPA-octreotide (Bioconjugate Chem. 1997,8,442-446). Iodine oxidation of the DTPA-peptide produced DTPA-D-Phe I -octreotide in overall 31.8% yield based on the starting Fmoc-Thr(tBu)-ol-resin. 
     Wu et al developed a method to synthesis of octreotide (Tetrahedron Letters 1998,39,1783-1784). The formation of the disulfide bond was oxidized using a dilution solution of octreotide with air and spent 48 hours. Lee et al recently have carried out a new method to anchor Thr(ol) to a solid phase synthesis resin for preparation of octreotide (U.S. Pat. No. 5,889,146, 1999). Fmoc-Thr(ol)-terephthal-acetal was loaded onto the resin. After construction of peptide chains by Fmoc chemistry, cyclization of the peptide may be obtained on resin by oxidation with iodine. The cleavage of peptide-resin with trifluoroacetic acid, produced octreotide with overall yield of &gt;70% from the starting Fmoc-Thr(ol)-tere-phthal-acetal-resin. All of these procedures completed the cyclization of the octreotide either on totally deprotected peptide or on the resin. 
     SUMMARY OF THE INVENTION 
     The main object of the present invention is to provide a novel process for synthesis of octreotide and derivatives thereof. The starting material, Thr(ol)(tBu)-2-chlorotrityl resin is coupled with the various amino acids. The straight peptide-resin, such as 
     D-Phe-Cys(Trt)-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(ol)(tBu)-2-chlorotrityl resin or 
     D-Phe-Cys(Trt)-Tyr(tBu)-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(ol)(tBu)-2-chlorotrityl resin was obtained. Cleavage of the peptide from the resin was achieved by strong acid solution. 
     The cleaved peptide reacted with charcoal to give disulfide-containing peptide as following:                           
     Purification of the crude peptide was obtained by chromatography. The novel process in this invention for synthesis of octreotide and derivative thereof has been proved to be more time-saving, higher yield &gt;80%, and easier for separation from the reaction system than the prior art is. 
     DETAILED DESCRIPTION OF THE INVENTION 
     The following abbreviations are employed: 
     Fmoc: 9-fluorenylmethoxycarbonyl 
     Boc: t-butyloxycarbonyl 
     tBu: tert-butyl 
     Trt: triphenylmethyl 
     Thr(ol): the threoninol residue 
     Phe: the phenylalanine residue 
     Cys: the cysteine residue 
     Thr: the threonine residue 
     Lys: the lysine residue 
     Trp: the tryptophan residue 
     Tyr: the tyrosine residue 
     TFA: trifluoroacetic acid 
     EDT: 1,2-ethanedithiol 
     THF: tetrahydrofuran 
     HBTB: Benzotriazolyloxytetramethyluronium hexafluorophosphate 
    
    
     EXAMPLE 1-1 
     Synthesis of D-Phe-Cys(Trt)-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(ol)(tBu)-2-chlorotrityl resin. 
     Thr(ol)(tBu)-2-chlorotrityl resin (1.0 mmol, 1.25 g) was used as the starting material for solid phase peptide synthesis. Fmoc-Cys(Trt)-OH (3 mmol, 1.75 g) was activated by using HBTU. In the coupling step, the activated Fmoc-Cys(Trt)-OH reacted with Thr(ol)(tBu)-2-chlorotrityl resin to form Fmoc-Cys(Trt)-Thr(ol)(tBu)-2-chlorotrityl resin. The Fmoc protecting group of Fmoc-Cys(Trt)-Thr(ol)(tBu)-2-chlorotrityl resin was removed by piperidine. Activating, coupling and deprotecting steps are repeated with each subsequent amino acid until an assembly chain D-Phe-Cys(Trt)-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(ol)(tBu)-2-chlorotrityl resin has been completed. The peptide resin was dried in vacuo and weighted to be 2.89 g. 
     EXAMPLE 1-2 
     Synthesis of D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol) 
     The D-Phe-Cys(Trt)-Phe-D-Trp(Lboc)-Lys(Boc)-Thr(tBu)-cys(Trt)-Thr(ol)(tBu)-2-chlorotrityl resin (2.89 g) was cleaved with 9.5%TFA-2.5%EDT-2.5%H 2 O solution at room temperature for 1.5 hours. The cleavage mixtures were dried to about 0.5˜1.0 ml under vacuum. After adding with equal volume of ice-cold ether, these extracts were centrifuged. The pellets were collected and washed with cold dry ether. The cleavage products were extracted with 50% acetonitrile and dried by lyophilization to white powder. The crude peptide (0.9 g) was obtained and analyzed on a Waters HPLC, consisting of two 600E solvent pumps and a Waters 991 photodiode detector. Injections of 50 μl were eluted at a flow rate of 1.6 ml/min from a 10×250 mm C-18 reverse phase column, minitored at 280 nm. A 30 min linear gradient, from 80%˜20% A (solvent A: 0.1% TFA in H 2 O; solvent B: 0.1% TFA in acetonitrile) was used. The major peak at a retention time of 22.3 min was collected. ESMS analysis of the isolated peak showed [M+H] + =1021.8 Da. 
     EXAMPLE 1-3 
     
       
                 
         
             
             
         
      
     
     The D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)(0.9 g) dissolved in H 2 O to final concentration of 100 mg/ml. The solution was adjusted with 10% sodium hydroxide to pH 8.0. After adding with equal volume of acetonitrile, granulated charcoal (trace amount) was added to peptide solution. The resulting mixture was then stirred at room temperature for 5 hours and separated by filtration with 0.45 um PVDF membrane. The filtrate was dried by lyophilization to white powder. The crude peptide (0.85 g) was purified by chromatography using carboxy-methoxy-sepharose gel. 
     Analytical RP-HPLC of the octreotide was performed on a 10×250 mm C-18 column using a gradient of 80%˜20% A in 30 min at a flow rate of 1.6 ml/min where A=0.1% TFA in H 2 O and B=0.1% TFA in acetonitrile. The product peak eluting at 20.7 min gave [M+H] + =1019.8 Da by ESMS. 
     EXAMPLE 2-1 
     Synthesis of D-Phe-Cys(Trt)-Tyr(tBu)-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(ol)(tBu)-2-chlorotrityl resin. 
     Thr(ol)(tBu)-2-chlorotrityl resin (1.0 mmol. 1.25 g) was used as the starting material for solid phase peptide synthesis. Fmoc-Cys(Trt)-OH (3.0 mmol, 1.75 g) was activated by using HBTU. In the couplings step. the activated Fmoc-Cys(Trt)-OH reacted with Thr(ol)(tBu)-2-chlorotrityl resin to form Fmoc-Cys(Trt)-Thr(ol)(tBu)-2-chlorotrityl resin. The Fmoc protecting group of Fmoc-Cys(Trt)-Thr(ol)(tBu)-2-chlorotrityl resin was removed by piperidine. Activating, coupling and deprotecting steps are repeated with each subsequent amino acid until an assembly chain D-Phe-Cys(Trt)-Tyr(tBu)-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(ol)(tBu)-2-chlorotrityl resin has been completed. The peptide resin was dried in vacuo and weighted to be 2.91 g. 
     EXAMPLE 2-2 
     Synthesis of D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr(ol) 
     The D-Phe-Cys(Trt)-Tyr(tBu)-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(ol)(tBu)-chlorotrityl resin (2.91 g) was cleaved with 95%TFA-2.5%EDT-2.5%H 2 O solution at room temperature for 1.5 hours. The cleavage mixtures were dried to about 0.5˜1.0 ml under vacuum. After adding with equal volume of ice-cold ether, these extracts were centrifuged. The pellets were collected and washed with cold dry ether. The cleavage products were extracted with 50% acetonitrile and dried by lyophilization to white powder. The crude peptide (0.9 g) was obtained and analyzed on a Waters HPLC, consisting of two 600E solvent pumps and a Waters 991 photodiode detector. Injections of 50 μl were eluted at a flow rate of 1.6 ml/min from a 10×250 mm C-18 reverse phase column, minitored at 280 nm. A 40 min linear gradient, from 80%˜20% A (solvent A: 0.1%TFA in H 2 O; solvent B: 0.1%TFA in acetonitrile) was used. The major peak at a retention time of 20.2 min was collected. ESMS analysis of the isolated peak showed [M+H] + =1037.4 Da. 
     EXAMPLE 2-3 
     
       
                 
         
             
             
         
      
     
     The D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr(ol) (0.9.g) dissolved in H 2 O to final concentration of 100 mg/ml. The solution was adjusted with 10% sodium hydroxide to pH8.0. After adding with equal volume of acetonitrile. granulated charcoal (trace amount) was added to peptide solution. The resulting mixture was then stirred at room temperature for 5 hr and separated by filtration with 0.45 μm PVDF membrane. The filtrate was dried by lyophilization to white powder. The crude peptide (0.85 g) was purified by chromatography using carboxy-methoxy-sepharose gel. Analytical RP-HPLC of the Tyr-3-octreotide was performed on a 10×250 mm C-18 column using a gradient of 80%˜20% A in 30 min at a flow rate 1.6 ml/min where A=0.1%TFA in H 2 O and B=0.1%TFA in acetonitrile. The product peak eluting at 18.5 min gave [M+H] + =1019.8 Da by ESMS.